Oncology
Nitroreductase mutants improve cell sensitivity to chemotherapy
Published in Gene Therapy Weekly, November 13th, 2003
According to recent research from England, "Escherichia coli nitroreductase (NTR) activates the prodrug CB1954 to a cytotoxic derivative, allowing selective sensitization of NTR-expressing cells or tumors to the prodrug. This is one of several enzyme-prodrug combinations that are under development for cancer gene therapy, and the system has now entered clinical trials. Enhancing the catalytic efficiency of NTR for CB1954 could improve its therapeutic potential."
"From the crystal structure of an enzyme-ligand complex, we identified nine amino acid residues within the active site...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2003-11-13)
More Articles from Gene Therapy Weekly
- Gene Transfer
Human serum albumin-polyethylenimine nanoparticles power transfection ability - Genomics
Genes that induce proliferation are strategic targets for human therapy - Antisense Technology
A new method optimizes antisense oligonucleotide transfer to CD8+ T cells - Gene Therapy
Reductase enzymes potentiate how indolequinones attack cancer cells - Gene Transfer
BAD overexpression improves the way anchorage-loss encourages apoptosis - Biosynthesis
New RNase P ribozymes are feasible for use in gene-targeting applications - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
